Illumina Inc. is a leading biotechnology company that specializes in genetic sequencing and analysis. The company was founded in April 1998 and is headquartered in San Diego, California. Illumina's primary mission is to improve human health by unlocking the power of the genome.
Illumina develops and manufactures innovative platforms and systems for genetic sequencing, including instruments, consumables, and software solutions. The company's technology enables researchers and clinicians to analyze genetic information on a massive scale, providing insights into various applications such as cancer research, reproductive health, genetic disease diagnosis, and precision medicine.
One of Illumina's groundbreaking contributions to the field of genomics is the development of high-throughput DNA sequencing systems. These platforms, such as the NovaSeq and HiSeq series, have revolutionized the field by enabling researchers to sequence and analyze large volumes of genetic data quickly and cost-effectively.
Illumina went public on July 28, 2000, with its initial public offering (IPO) on the NASDAQ stock exchange under the ticker symbol "ILMN." Since then, the company has experienced significant growth and has become a key player in the genomics industry. Illumina's products and services are widely used by academic institutions, research organizations, pharmaceutical companies, and clinical laboratories worldwide.
With its advanced sequencing technologies and data analysis tools, Illumina has contributed to numerous scientific discoveries and advancements in genomic research. The company's efforts have paved the way for personalized medicine and have opened new possibilities for understanding and treating diseases at the genetic level.
In addition to its research and development activities, Illumina collaborates with various partners and organizations to promote the use of genomics in healthcare. The company has formed partnerships with academic institutions, government agencies, and industry leaders to advance genomic research and facilitate the integration of genomics into clinical practice.